Alkermes PLC (NASDAQ: ALKS) saw its stock price surge 5.02% in intraday trading on Thursday, as the biopharmaceutical company's strong financial performance and positive outlook fueled investor optimism.
The company reported robust fiscal year 2024 results, with total revenue exceeding $1.5 billion, driven by its proprietary commercial portfolio. Notably, Alkermes achieved over $450 million in EBITDA from continuing operations and ended the year debt-free with a solid cash position of $825 million.
Key products like VIVITROL, ARISTADA, and LYBALVI demonstrated growth, with LYBALVI's net sales increasing by an impressive 46% year-over-year in 2024. Moreover, Alkermes is expanding its psychiatry sales team by approximately 80 representatives to maintain a strong competitive position in the market.
Investors are also optimistic about Alkermes' pipeline candidate ALKS 2680 for narcolepsy, which showed promising results in Phase Ib trials. The company plans to pursue accelerated pathways to market after completing the ongoing Phase II studies and meeting with regulatory authorities.
Several analysts have maintained positive ratings and price targets on Alkermes, citing the company's underlying strength and favorable outlook. H.C. Wainwright, for instance, reiterated a Neutral rating with a $46 price target, while Mizuho Securities maintained a Buy rating following the Q4 2024 earnings report.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。